Core Insights - SciSparc Ltd. has signed a definitive agreement to acquire a portfolio of patents, trademarks, and intellectual property rights for innovative endoscopic systems, including the MUSE™ system, from Xylo Technologies Ltd. [1][4] - The MUSE™ system is designed for transoral fundoplication, a minimally invasive procedure for treating gastroesophageal reflux disease (GERD) [2] - SciSparc plans to commercialize these technologies immediately after the transaction closes, aiming for rapid market penetration and revenue generation [2] Company Strategy - Building on Xylo's previous success in Greater China, where it generated $3 million through a licensing agreement, SciSparc intends to replicate this model in high-growth markets such as North America, Europe, and Latin America [3] - The company aims to establish exclusive partnerships with leading regional distributors to accelerate global commercialization and unlock significant revenue streams [3] Financial Terms - As part of the acquisition, SciSparc will issue ordinary shares to Xylo, representing 19.99% of the issued and outstanding share capital of SciSparc upon closing, scheduled for March 8, 2026 [4] - The transaction is subject to customary closing conditions, including regulatory approvals [5] Market Context - The global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, with a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030 [5]